Table 1.
Patient characteristics
| Variable | All patients |
|---|---|
| (n = 146) | |
| Overall age at consent, y | |
| Mean (SD) | 57 (12.2) |
| Range, y | 28-81 |
| Race, No. (%) | |
| White | 110 (75.3) |
| African American | 23 (15.8) |
| Other | 13 (8.9) |
| Breast cancer stage, No. (%)a | |
| I | 32 (21.9) |
| II | 81 (55.5) |
| III | 33 (22.6) |
| Phenotype, No. (%) | |
| Hormone receptor–positive and HER2-negative | 74 (50.7) |
| Hormone receptor–negative and HER2-negative (triple negative) | 42 (28.8) |
| HER2-positive and hormone receptor–negative | 14 (9.6) |
| HER2-positive and hormone receptor–positive | 16 (11.0) |
| Timing of chemotherapy, No. (%) | |
| Neoadjuvant | 54 (37.0) |
| Adjuvant | 91 (62.3) |
| Both | 1 (0.7) |
| Treatment regimens, No. (%) | |
| AC-T (doxorubicin and cyclophosphamide then paclitaxel and carboplatin)b | 53 (36.3) |
| AC-TC (doxorubicin and cyclophosphamide then paclitaxel and carboplatin)c | 17 (11.6) |
| TC (docetaxel and cyclophosphamide)d | 51 (34.9) |
| TCH (docetaxel and carboplatin + anti-HER2 therapy)e | 25 (17.1) |
a
American Joint Committee on Cancer stage version 7.
b
Nine patients had paclitaxel before doxorubicin and cyclophosphamide. Doxorubicin and cyclophosphamide given every 2 weeks with growth factors (5 patients got anthracycline every 3 weeks); 3 patients received anti-HER2 therapy with AC-T.
c
TC given first in 11 patients.
d
Given every 3 weeks with growth factors; 2 patients received anti-HER2 therapy with TC.
e
Given every 3 weeks with growth factors; all received trastuzumab, and 19 patients received pertuzumab in addition to trastuzumab.